Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United Kingdom
/
Pharmaceuticals & Biotech
/
GSK
GSK
GSK
US Inflation Reduction Act And Patent Cliffs Will Erode Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 18 Analysts
Published
04 Jun 25
Updated
23 Jul 25
1
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
UK£11.20
22.6% overvalued
intrinsic discount
23 Jul
UK£13.73
Loading
1Y
-10.6%
7D
-6.1%
Author's Valuation
UK£11.2
22.6% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
UK£11.2
22.6% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
35b
2014
2017
2020
2023
2025
2026
2028
Revenue UK£34.4b
Earnings UK£6.5b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.06%
Pharma revenue growth rate
1.11%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.82%
Calculation
UK£6.47b
Earnings '28
x
8.51x
PE Ratio '28
=
UK£55.10b
Market Cap '28
UK£55.10b
Market Cap '28
/
4.10b
No. shares '28
=
UK£13.44
Share Price '28
UK£13.44
Share Price '28
Discounted to 2025 @ 6.64% p.a.
=
UK£11.08
Fair Value '25